OncoMatch/Clinical Trials/NCT05819853
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Is NCT05819853 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Semaglutide Injectable Product (Wegovy and/or Ozempic) for pcos (polycystic ovary syndrome) of bilateral ovaries.
Treatment: Semaglutide Injectable Product (Wegovy and/or Ozempic) — Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
Hemoglobin ≥ 12 mg/dL
Anemia, defined as Hemoglobin < 12 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Anschutz/Children's Hospital Colorado Aurora · Aurora, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05819853 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 35 years or younger and at least 12 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify